Fintel reports that on September 4, 2026, Canaccord Genuity initiated coverage of Belite Bio, Inc - Depositary Receipt (NASDAQCM:BLTE) with a Buy recommendation. Prior to this action, the stock closed at $171.09 on September 3, 2026, and subsequently closed at $193.61 on September 4, 2026.
Belite Bio, Inc, based in the United States, is a biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of age-related and orphan retinal diseases. The company's strategic emphasis is on addressing significant unmet medical needs in ocular diseases that cause blindness, such as Stargardt disease and age-related macular degeneration. Belite Bio has several key projects in various stages of clinical development aimed at creating innovative solutions that can prevent, manage, or treat these debilitating eye diseases. In its latest earnings report on August 12, 2026, the company reported an actual EPS of -0.7, compared to an estimated EPS of -0.8045. Both actual revenue and estimated revenue for the period were reported at $0.00.
The stock has experienced notable price movements, with a one-week price change of +27.61% from a baseline close of $151.72 on August 28, 2026. Over a one-month period, the price changed by +23.11% from a baseline close of $157.27 on August 4, 2026. Separately, as of August 28, 2026, the current consensus target mean for the stock was $218.28, representing an implied change of +12.74% from previous levels, with a median target of $214.20. This is an increase from the prior consensus target mean of $214.71 recorded on August 4, 2026, reflecting a consensus target revision of +1.66%.
As of September 1, 2026, the aggregate recommendation consensus for Belite Bio, Inc consisted of 4 strong buy, 9 buy, 1 hold, 0 sell, and 0 strong sell recommendations, totaling 14 recommendations. This represents 92.9% positive, 7.1% hold, and 0.0% negative recommendations, which remains unchanged from the prior recommendation period on August 1, 2026. Other recent analyst actions include Morgan Stanley maintaining an Overweight rating on August 14, 2026, Cantor Fitzgerald maintaining an Overweight rating on August 14, 2026, and HC Wainwright & Co. maintaining a Buy rating on August 12, 2026.
Recent analyst actions
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
